Document:

EX-10.23

 Exhibit 10.23 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 GLOBAL ACCESS AND PRICE COMMITMENT AGREEMENT 

Investment ID [***] 
 This Global Access and
Price Commitment Agreement (“Agreement”), effective as of the date of the last signature below, is made by and between the Bill & Melinda Gates Foundation (the “Foundation”) and Icosavax, Inc.
(“Icosavax”), in connection with the Grant Agreement for [***] between the Parties effective September 24, 2020 (“Grant Agreement”). Unless otherwise defined in this Agreement, capitalized terms
have the same meaning as given in the Grant Agreement. This Agreement is a part of, and is incorporated into, the Grant Agreement. 
  

	1.	 Charitable Purpose and Use of Funds 

The Foundation wishes to encourage innovative approaches to ensuring the wide availability of affordable, safe, and effective lifesaving vaccines for use in
Eligible Countries (as defined below), which is expected to significantly improve health outcomes for those most in need in such countries, and in particular to encourage the supply of safe and effective vaccines that vaccinate against covid-19 (“Covid”), which are produced at a price and on a timeline that meets the critical needs for achieving the goal of expanding the supply of such vaccines for the Eligible Countries
(the “Charitable Purpose”). 
 Icosavax possesses expertise and experience in the development and manufacturing of vaccines
using a nanoparticle display technology. Icosavax is in the process of developing and manufacturing a two-component (i.e., Components A and B) virus-like particle containing the receptor binding domain for SARS-Cov-2 using Icosavax’s proprietary technology for pandemic use, which is anticipated to be available in multi-dose vials (the “Covid
Vaccine”). 
 In furtherance of the Charitable Purpose, the Foundation has provided grant funding to Icosavax in accordance with the Grant
Agreement, to, among other things, (i) assemble Components A and Components B into the Covid Vaccine, and related fill and finish, (ii) develop regulatory submission-enabling data regarding the Covid Vaccine, and (iii) conduct a Phase
1 study to assess safety and immunogenicity of the Covid Vaccine in healthy adults and older adults. Pursuant to the Grant Agreement, Grant Funds will be used solely to fund the Project. 

 

	2.	 Definitions  

The following terms shall have the following meanings: 

[***] 
 “Annual
Period” means each 12-month period commencing on the date that Icosavax and/or its manufacturing and/or commercial partner(s) commenced supplying Covid Vaccine to a Public Sector Purchaser. The
first Annual Period is referred to as Annual Period 1 and so forth. 

  
 1 

 “Annual Volume Commitment” has the meaning given in
Section 3(b)(iii). 
 “Annual Volume Commitment Term” has the meaning given in
Section 3(b)(iv). 
 “Cost of Goods Sold” or “COGS” means the
total cost of production, manufacturing, packaging, temperature monitoring devices as required by WHO guidelines on the international packaging and shipping of vaccines (WHO/IVB/05.23) or any later revision, vaccine vial monitors, and delivery in
accordance with INCOTERM FCA to the designated airport as determined in accordance with the Foundation’s COGS Principles and Assessment Methodology Handbook available at:
https://docs.gatesfoundation.org/Documents/Production_Economics_Vaccines_2016.pdf, which may be modified from time to time. 

“Eligible Countries” means all GAVI Eligible Countries and GAVI Transitioned Countries plus other Low and Low-Middle Income Countries as identified by the World Bank and any other counties eligible for financial support by the GAVI COVAX AMC. As of the date of the last signature below, Eligible Countries consist of
those countries listed in Exhibit A. Based on the definition of Eligible Countries as set forth in this Section 2, countries may be removed from or added to Exhibit A. 

“GAVI Eligible Countries” means all countries which are deemed GAVI-eligible countries by GAVI, including those in
preparatory or accelerated transition, as such GAVI-eligible countries may be added or deleted by the GAVI from time to time. 

“GAVI Transitioned Countries” means all countries which were at one time deemed GAVI-eligible countries by GAVI. 

“Government or Governmental Authority” means (i) the government of the United States, or any other state,
provincial, local, or foreign government (as applicable), and any department, subdivision, agency, or authority of any of the forgoing or (ii) any court, tribunal or regulatory body having competent jurisdiction over Icosavax, the Foundation,
Covid Vaccine, or any of the transactions contemplated by this Agreement, as applicable. 
 “Person” means
(i) an individual; (ii) a partnership, a limited liability partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, an estate, or any other type of entity; (iii) a joint venture;
(iv) an unincorporated organization; (v) a Government or Governmental Authority; or (vi) any non-governmental organization not otherwise covered by the foregoing. 

“Price Commitment” has the meaning given in Section 3(b)(ii). 

“Project” shall mean the project described in the Investment Document referenced in the Grant Agreement. 

“Public Sector Purchaser” shall mean any of the following seeking to purchase Covid Vaccine for use in an Eligible
Country: 

  
 2 

 (i)    Governments including government ministries and agencies,
together with government-funded institutions, such as hospitals and prison services in those countries; 
 (ii)    NGOs
including those recognized by the applicable local government authority as well as UN-related organizations working for or in those countries, including the International Organization for Migration and UNICEF,
WHO, or any other UN agency; 

(iii)    Not-for-profit organizations
including, but not limited to, Medecins Sans Frontieres, Save-the-Children, OXFAM and the International Committee of the Red Cross; 

(iv)    Public private partnerships that have agreed to public pricing or other collaborations or institutions bringing WHO-approved vaccines at affordable prices to patients in the private sector, including, but not limited to, GAVI; and 

(v)    Funding mechanisms including CEPI, GDF, UNITAID, UNFPA, PEPFAR, USAID, Global Fund, etc. and agencies based outside
of an applicable Eligible Country but which are supporting implementation locally in an applicable country, including the USA-CDC and The European Union. 

“Supply Agreement” means a supply agreement for [***] and information related thereto for use solely with the Covid
Vaccine (including [***]) to be negotiated in good faith between Icosavax and [***], anticipated to provide for the commercial supply of up to [***] of [***] for use solely with the Covid Vaccine. 

“Total Annual Doses” means the total number of doses of Covid Vaccine produced by Icosavax and/or its manufacturing
and/or commercial partner(s) in a given 12-month period commencing on the date that Icosavax and/or its manufacturing and/or commercial partner(s) commenced supplying Covid Vaccine to a Public Sector
Purchaser. 
 “WHO Prequalification” means the positive written advice provided by the WHO to United Nations
agencies of the acceptability of Covid Vaccine for purchase by United Nations agencies and the inclusion of Covid Vaccine on the list of pre-qualified vaccines for such purchase. 

 

	3.	 Global Access Commitments 

In furtherance of the Charitable Purpose, Icosavax agrees to the following “Global Access Commitments”: 

 

	 	(a)	 Prompt and Broad Dissemination of Knowledge and Information. Consistent with the Publication provisions
of the Grant Agreement, Icosavax will use reasonable and diligent steps to publish results of the Project in one or more peer reviewed journal(s). In the event of an inability to obtain peer reviewed publication, Icosavax agrees to publish in a
manner that the Foundation determines in its reasonable discretion satisfies the requirement that such research be published in a form that is “available to the interested public” as described in Treasury Regulation 1.501(c)(3)-1(d)(5)(iii)(c)(2). 

  
 3 

	 	(b)	 Continued Development. In the event of successful completion of the Phase 1 study of the Covid Vaccine
as described in the Project, and the Foundation has made all payments to Icosavax in accordance with the terms of the Grant Agreement, Icosavax will take reasonable steps to obtain additional funding for completing the activities necessary to
further develop the Covid Vaccine beyond the Phase 1 study. Within [***] of the [***], Icosavax will have received or will have a [***] to further develop, manufacture, and/or distribute the Covid Vaccine. If Icosavax [***] and continues the
development and commercialization of the Covid Vaccine, the following terms apply: 

  

	 	(i)	 Regulatory Commitment. Icosavax will ensure that the Essential Background Technology and Funded
Developments it owns or controls now or in the future are managed in a manner to support the relevant regulatory approvals and WHO Prequalification of the Covid Vaccine. 

 

	 	(ii)	 Price Commitment. Icosavax will ensure that it or its manufacturing and/or commercial partner(s) sell
the Covid Vaccine to Public Sector Purchasers for use in Eligible Countries for the Charitable Purpose at no more than [***] above the combined COGS for Covid Vaccine [***] (the “Price Commitment”). 

 

	 	(iii)	 Annual Volume Commitment. Upon obtaining applicable regulatory approvals and in accordance with
applicable laws, Icosavax will use reasonable efforts to ensure that it or its manufacturing and/or commercial partner(s) will manufacture, package, label, store and ship the quantities of Covid Vaccine necessary to fulfill all purchase orders
awarded and bound to Icosavax and/or its manufacturing and/or commercial partner(s) from Public Sector Purchasers to purchase Covid Vaccine for use in the Eligible Countries for the Charitable Purpose in the following quantity:

  

	 	a.	 an annual capacity available to Eligible Countries that is at least [***] of Icosavax’s Total Annual Doses
(the “Annual Volume Commitment”). 

  

	 	(iv)	 Annual Volume Commitment Term. Icosavax and/or its manufacturing and/or commercial partner(s) will
provide the Annual Volume Commitment for a [***] period commencing on the date of first supplying the Covid Vaccine to a Public Sector Purchaser and ending on the [***] anniversary thereof (the “Annual Volume Commitment
Term”). 

  

	 	(v)	 Manufacturing and Supply. Before finalizing a partnership with its manufacturing and/or commercial
partner(s), Icosavax will ensure that its agreement(s) with these manufacturing and/or commercial partner(s) have appropriate provisions to support the furtherance of Global Access for the Charitable Purpose, including assurances that the Covid
Vaccine will be provided at the Price Commitment and Annual Volume Commitment outlined above consistent with this Agreement. 

  
 4 

	 	(vi)	 Termination of Price and Volume Commitments. If, for [***], Icosavax and/or its manufacturing and/or
commercial partner(s) fulfill all of their obligations pursuant to Section 3(b)(i)-(v) and through no fault of Icosavax and/or its manufacturing and/or commercial partner(s) there are insufficient purchase
orders to enable Icosavax and/or its manufacturing and/or commercial partner(s) to sell at least [***] of Icosavax’s Total Annual Doses of Covid Vaccine, for each Annual Period, then the applicable Price Commitment and Annual Volume Commitment
set forth in Section 3(b)(ii) and Section 3(b)(iii) shall terminate beginning with the next Annual Period, and the Foundation and Icosavax will meet and discuss in good faith the applicable Price
Commitment and Annual Volume Commitment for the remaining Annual Periods. 

  

	 	(vii)	 Insufficient Supply to Meet Global Demand. If global demand for the Covid Vaccine by Public Sector
Purchasers exceeds Icosavax’s and/or its manufacturing and/or commercial partner(s)’ Annual Volume Commitment, the Parties shall discuss in good faith the solution to meet such global demand, including without limitation additional funding
to increase Icosavax’s and/or its manufacturing and/or commercial partner(s)’ annual capacity. If the Parties fail to reach an agreement, Icosavax will in good faith cooperate with the Foundation in making available the Funded Developments
and Essential Background Technology relating to the Project available to the Foundation (or any other Person designated by the Foundation) and provide adequate tech transfer (under non-exclusive licenses with
terms to be negotiated in good faith), to continue to develop the Covid Vaccine and to enable the use, design, research, development, production, manufacture, sale, distribution, import, or export of the Covid Vaccine solely for use in the Eligible
Countries for the Charitable Purpose. 

  

	 	(viii)	 ACT-A Coordination. At the Foundation’s request, the
Parties agree to negotiate in good faith to modify and amend this Agreement, including the Global Access Commitments, to align with any applicable allocation, procurement and/or coordination mechanism established under the Access to Covid-19 Tools Accelerator, a WHO-led Global Collaboration to accelerate the development, production and equitable access to new
Covid-19 diagnostics, therapeutics and vaccines.  

  

	 	(ix)	 Discontinued Activities. In the event Icosavax and its manufacturing and commercial partner(s) decide to
discontinue with the development, manufacture, supply and/or distribution of the Covid Vaccine for any reason, if requested by the Foundation, Icosavax will in good faith cooperate with the Foundation in making available the Funded Developments and
Essential Background Technology relating to the Project available to the Foundation (or any other Person designated by the 

  
 5 

	 	
Foundation), as well as assigning the Supply Agreement for use of the [***] with the Covid Vaccine, and provide adequate tech transfer (under non-exclusive
licenses with terms to be negotiated in good faith), to continue to develop the Covid Vaccine and to enable the use, design, research, development, production, manufacture, sale, distribution, import, or export of the Covid Vaccine solely for use in
the Eligible Countries for the Charitable Purpose. 

  

	 	(c)	 Discontinued Development. In the event Icosavax is unable to obtain additional funding as described in
Section 3(b), if requested by the Foundation, Icosavax will in good faith cooperate with the Foundation in making available the Funded Developments and Essential Background Technology relating to the Project to the Foundation (or any other
Person designated by the Foundation), as well as assigning the Supply Agreement for use of the [***] with the Covid Vaccine, and provide adequate tech transfer (under non-exclusive licenses with terms to be
negotiated in good faith) to continue to develop the Covid Vaccine and to enable the use, design, research, development, production, manufacture, sale, distribution, import, or export of the Covid Vaccine solely for use in the Eligible Countries for
the Charitable Purpose. 

  

	4.	 Intellectual Property Rights. To Icosavax’s knowledge, Icosavax owns or has and will own or have a
valid license to all Essential Background Technology necessary for the development of the Covid Vaccine in accordance with the terms of this Agreement and the Grant Agreement. To Icosavax’s knowledge as of the date hereof, the manufacture or
sale of the Covid Vaccine by Icosavax in accordance with this Agreement does not infringe any intellectual property rights of a third party to which Icosavax does not hold a valid license. Except to the extent expressly provided in this Agreement
and the Grant Agreement, nothing in this Agreement shall be construed to confer any ownership interest, license or other rights upon the Foundation or any of its Affiliates or any Foundation-supported entity by implication, estoppel or otherwise as
to any technology, intellectual property rights, products or materials of Icosavax or any other entity. 

  

	5.	 [***]. Prior to the start of the Phase 1 clinical study for the Covid Vaccine contemplated by the
Project, Icosavax will have entered into an agreement for the use of [***] and information relating thereto for use in such Phase 1 clinical study. Prior to the start of the Phase III clinical study for the Covid Vaccine, Icosavax will have entered
into the Supply Agreement. Notwithstanding anything contained in this Agreement and the Grant Agreement, in no event will the Funded Developments or any data or results relating to the [***] or the [***] be used in the development,
commercialization, or sale of a product containing [***]. For the avoidance of doubt, this Section 5 only applies to use of data or results generated relating to [***] and/or the Covid Vaccine developed by Icosavax as described in this
Agreement and the Grant Agreement and does not preclude the independent development (without the use of such data or results) of [***] for other target disease areas of interest to the Foundation and its relevant geographies. 

 

	6.	 Entire Agreement, Conflicts, and Amendments. This Agreement and the Grant Agreement
contain the entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject matter. Except as specifically permitted in this Agreement

  
 6 

	 	
and the Grant Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties.

 [Signature Page Follows] 

  
 7 

 This Global Access and Price Commitment is executed by the Parties effective as of the last date of
signature below. 
  

							
	Icosavax, Inc.	  	Bill & Melinda Gates Foundation
				
	By:	 	 /s/ Adam Simpson
	  	By:	 	 /s/ Harry Kleanthous

				
	Print:	 	 Adam Simpson
	  	Print:	 	 Harry Kleanthous

				
	Title:	 	 Chief Executive Officer
	  	Title:	 	 SPO D&TS Vaccines & Human Immunobiology

				
	Date:	 	 02/17/2021
	  	Date:	 	 02/16/2021

 Exhibit A 
  

	 	•	 	 Low income: 

Afghanistan, 
 Benin, 

Burkina Faso, 
 Burundi, 

Central African Republic, 
 Chad,

 Congo, Dem. Rep., 
 Eritrea,

 Ethiopia, 
 Gambia, 

The Guinea, 
 Guinea-Bissau, 

Haiti, 
 Korea, Dem. People’s
Rep., 
 Liberia, 
 Madagascar,

 Malawi, 
 Mali, 

Mozambique, 
 Nepal, 

Niger, 
 Rwanda, 

Sierra Leone, 
 Somalia, 

South Sudan, 
 Syrian Arab
Republic, 
 Tajikistan, 

Tanzania, 
 Togo, 

Uganda, 
 Yemen, Rep. 

 

	 	•	 	 Lower-middle income: 

Angola, 
 Algeria, 

Bangladesh, 
 Bhutan, 

Bolivia, 
 Cabo Verde, 

Cambodia, 
 Cameroon, 

 Comoros, 

Congo, 
 Rep. Côte
d’Ivoire, 
 Djibouti, 

Egypt, Arab Rep., 
 El Salvador,

 Eswatini, 
 Ghana, 

Honduras, 
 India, 

Indonesia, 
 Kenya, 

Kiribati, 
 Kyrgyz Republic, 

Lao PDR, 
 Lesotho, 

Mauritania, 
 Micronesia, Fed.
Sts., 
 Moldova, 
 Mongolia,

 Morocco, 
 Myanmar, 

Nicaragua, 
 Nigeria, 

Pakistan, 
 Papua New Guinea, 

Philippines, 
 São
Tomé and Principe, 
 Senegal, 

Solomon Islands, 
 Sri Lanka, 

Sudan, 
 Timor-Leste, 

Tunisia, 
 Ukraine, 

Uzbekistan, 
 Vanuatu, 

Vietnam, 
 West Bank and Gaza,

 Zambia, 
 Zimbabwe 

 

	 	•	 	 Additional IDA eligible: 

Dominica, 
 Fiji, 

Grenada, 

 Guyana, 

Kosovo, 
 Maldives, 

Marshall Islands, 
 Samoa, 

St. Lucia, 
 St. Vincent and the
Grenadines, 
 Tonga, 
 Tuvalu.EX-10.24

 Exhibit 10.24 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 Patent License Agreement 

Agreement No. [***] 
 This Patent License Agreement is between the
Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”). 
 No binding agreement between the Parties will
exist until this Patent License Agreement has been signed by both Parties. Unsigned drafts of this Patent License Agreement shall not be considered offers. 

Background 
 Licensor owns or controls Patent
Rights. Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Patent Rights. Licensor has determined that such use, development, and commercialization of the Patent Rights is in the
public’s best interest and is consistent with Licensor’s educational and research missions and goals. Licensor desires to have the Patent Rights developed and used for the benefit of Licensee, the inventors, Licensor, and the public. 

NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the Parties hereby agree as follows: 

The Terms and Conditions of Patent License attached hereto as Exhibit A are incorporated herein by reference in their entirety (the “Terms and
Conditions”). In the event of a conflict between provisions of this Patent License Agreement and the Terms and Conditions, the provisions in this Patent License Agreement shall govern. Unless defined in this Patent License Agreement,
capitalized terms used in this Patent License Agreement shall have the meanings given to them in the Terms and Conditions. 
 The section numbers used in
the left hand column in the table below correspond to the section numbers in the Terms and Conditions. 
  

													
	1.    Definitions
	
            
	 	Effective Date	 	June 2, 2021
	 	 	Licensor	 	The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas
System, an agency of the State of Texas, whose address is 3925 W. Braker Lane, Suite 1.9A (R3500), Austin, Texas 78759.
	 	 	Licensee	 	Icosavax Inc., with its principal place of business at 1616 Eastlake Avenue E., Suite 208, Seattle,
WA 98102
	 	 	Contract Year and Contract Quarters	 	Contract Year is 12-month period ending on December 31
and Contract Quarters are 3-month periods ending on March 31, June 30, Sept. 30, Dec. 31
	 	 	Territory	 	Worldwide
	 	 	Field	 	 Field is
the Exclusive Field.
  
 “Exclusive Field” is defined as: all vaccine fields,
excluding mRNA based vaccines, for any use, including without limitation for the prevention, cure, amelioration or treatment of respiratory disease caused by metapneumovirus infection.

 
 All non-vaccine fields, such as test kits and
diagnostics, are also excluded.
  

													
	
            
	 	Patent Rights
	 	 	 App.
No./
 Date of Filing
	 	Title	  	Inventor(s)	 	Jointly Owned? (Y/N; if Y, with whom?)	 	Prosecution Counsel
	 	 	    [***]	 	    [***]	  	[***]	 	[***]	 	[***]

													
	
            
	 	USPTO Entity Status as of Effective Date	 	 Check one box:

☒ Small
 ☐ Large

													
	 2.4. Diligence Milestones

 

	
            
	 	Milestones and deadlines	 	 Milestone
Events
  
	 	
Deadlines
  

	 		 	Milestone 1: Submit report to Licensor for non-clinical immunogenicity studies
in animal models	 	[***]
	 		 	Milestone 2: Begin GMP manufacturing for clinical trials of Licensed Product	 	[***]
	 		 	Milestone 3: Dose first human patient with Licensed Product for Phase 1 Clinical Trials	 	[***]
	 		 	Milestone 4: Dose first human patient with Licensed Product for Phase 2b Clinical Trials	 	[***]
	 		 	Milestone 5: Dose first human patient with Licensed Product Phase 3 Clinical Trials	 	[***]
	 		 	Milestone 6: Marketing Approval of Licensed Product in the Territory by U.S. Food and Drug Administration or foreign
equivalent	 	[***]
	 3.    Compensation

 

	3.1(a)	 	Patent expenses due upon Effective Date	 	 Amount

 
	 	 based on invoices
received as of:
  

	 		 	[***]	 	April 8th, 2021
	3.1(b)	 	Milestone fees	 	 Milestone Events

 
	 	 Milestone Fees

 

	 		 	Milestone 1: Submit report to Licensor for non-clinical immunogenicity
studies in animal models	 	[***]
	 		 	Milestone 2: Begin GMP manufacturing for clinical trials of Licensed Product	 	[***]
	 		 	Milestone 3: Dose first human patient with Licensed Product for Phase 1 Clinical Trials	 	[***]
	 		 	Milestone 4: Dose first human patient with Licensed Product for Phase 2b Clinical Trials	 	[***]
	 		 	Milestone 5: Dose first human patient with Licensed Product Phase 3 Clinical Trials	 	[***]
	 	 	 	Milestone 6: Marketing Approval of Licensed Product in the Territory by U.S. Food and Drug Administration or
foreign equivalent	 	[***]

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA
	The University of Texas at Austin	 	Page 2	 	Agreement No. [***]

													
	 	 	 	 	Milestone 7: Net Product Sales of a Licensed Product incorporating licensed hMPV antigen of [***]	 	[***]
	 	 		 	Milestone 8: Net Product Sales of a Licensed Product incorporating licensed hMPV antigen of [***]	 	[***]
	            	 		 	Milestone 9: Net Product Sales of a Licensed Product incorporating licensed hMPV antigen of [***]	 	[***]
	3.1(c)	 	Scheduled license
fee payments	 	 [***] due on
Effective Date.
  
 [***] due on December 31 in Contract Years [***] through [***].

 
 [***] due on December 31 in Contract Years [***] and [***].

 
 [***] due on December 31 in every Contract Year beginning [***] and every Contract Year
until [***].

	3.1(d)	 	Sublicense Fees	 	 [***] of Non-Royalty Sublicensing Consideration received by Licensee before completion of Milestone [***] in section 2.4.
 [***] of Non-Royalty Sublicensing Consideration received by Licensee after completion of Milestone [***] in section 2.4 and before completion of Milestone [***] in section 2.4.

[***] of Non-Royalty Sublicensing Consideration received by Licensee after completion of Milestone [***] in section 2.4 and
before [***].
 [***] of Non-Royalty Sublicensing Consideration received by Licensee after [***].

	3.1(e)	 	Assignment fee	 	[***]
	3.2	 	Running royalty
rate (applies to
Sales by Licensee,
Affiliates
and
Sublicensees)	 	
[***] of Net Product Sales of Licensed Products that express only one unique antigen (“Single Vaccine Licensed Products”).

 
 [***] of Net Product Sales of Licensed Products that express more than one unique antigen
(“Multiple Vaccine Licensed Products”).

	3.2(c)	 	Stacking or third party royalty	 	If additional royalties are required to be paid to a Third Party for the use of such Third
Party’s patents in manufacturing and/or selling Licensed Products, royalties owed to Licensor may be reduced by [***] of royalties actually paid to the Third Party as set forth in Section 3.4 of the Terms and Conditions, except that the
royalty amount paid to Licensor shall not fall below [***] of Net Product Sales of Single Vaccine Licensed Products or [***] of Net Product Sales of Multiple Vaccine Licensed Products.
	3.3	 	Minimum royalty
(creditable to
royalties owed in
Contract Year)	 	
[***] due on December 31 in the first Contract Year after First Sale.
 [***] due
on December 31 in each Contract Year for years following such first Contract Year.

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA
	The University of Texas at Austin	 	Page 3	 	Agreement No. [***]

													
	3.5	 	Payment of ongoing patent costs	 	Licensee to pay [***] of ongoing patent costs. If an additional license is executed for this
technology for the mRNA Field, Licensee’s responsibility to reimburse ongoing patent costs shall be reduced to [***] of such costs.

					
	 18.
Contact Information

	
            
	 	
Licensee Contacts
	 	
Licensor Contacts

	 	 	 Contact for Notice:

[***]
  

With a copy to:

Icosavax, Inc.

1616 Eastlake Ave E., Suite 208,

Seattle, WA 98102
  

Accounting contact:
 ***]

 
 Patent prosecution contact:

[***]
	 	 Contact
for Notice:
 [***]
  

Payment and reporting contact:
 Checks payable to “The University of Texas at
Austin”
 [***]
  

Patent prosecution contact:

[***]

 20.  Reserved 

21.  No Other Promises and Agreements; Representation by Counsel.   Licensee expressly warrants and represents and does hereby
state and represent that no promise or agreement which is not herein expressed has been made to Licensee in executing this Patent License Agreement except those explicitly set forth herein and in the Terms and Conditions, and that Licensee is not
relying upon any other statement or representation of Licensor or its representatives. Licensee is relying on Licensee’s own judgment and has had the opportunity to be represented by legal counsel. Licensee hereby warrants and represents that
Licensee understands and agrees to all terms and conditions set forth in this Patent License Agreement and said Terms and Conditions. 

22.  Deadline for Execution by Licensee.  If this Patent License Agreement is executed first by the Licensor and is not
executed by the Licensee and received by the Licensor at the address and in the manner set forth in Section 18 of the Terms and Conditions within 30 days of the date of signature set forth under the Licensor’s signature below, then this
Patent License Agreement shall be null and void and of no further effect. 
 IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives
to execute this Patent License Agreement. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA
	The University of Texas at Austin	 	Page 4	 	Agreement No. [***]

									
	LICENSOR: THE UNIVERSITY OF TEXAS AT AUSTIN 
ON BEHALF OF THE BOARD OF REGENTS 
OF THE UNIVERSITY OF TEXAS SYSTEM	 		 	LICENSEE: Icosavax, Inc.
					
	By	 	 /s/ Les
Nichols                                        
        
	 		 	By	 	 /s/ Adam
Simpson                                        
    

									
			
	Les Nichols	 		 	 Adam Simpson

			
	Director	 		 	 Chief Executive Officer

				
	Office of Technology Commercialization	 		 	Date	 	 June 4,
2021                        

					
	Date	 	 June 3,
2021                    
	 		 		 	

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA
	The University of Texas at Austin	 	Page 5	 	Agreement No. [***]

 EXHIBIT A 

Terms and Conditions of Patent License 
 These Terms and Conditions of
Patent License (“Terms and Conditions”) are incorporated by reference into the Patent License Agreement to which they are attached. All Section references in these Terms and Conditions shall be references to provisions in these Terms and
Conditions unless explicitly stated otherwise. 
  

	1.	 Definitions 

“Affiliate” means corporation, firm, limited liability company, partnership or other entity that directly or indirectly Controls or is
Controlled by or is under common control with Licensee. For purposes of this definition, “Control” means (i) having the actual, present capacity to elect a majority of the directors of such entity; (ii) having the power to
direct at least fifty percent (50%) of the voting rights entitled to elect directors; or (iii) in any country where the local law will not permit foreign equity participation of a majority, ownership or control, directly or indirectly, of the
maximum percentage of such outstanding stock or voting rights permitted by local law. 
 “Agreement” means collectively
(i) these Terms and Conditions, and (ii) the Patent License Agreement. 
 “Contract Quarter” means any three-month period
indicated as the Contract Quarter in Section 1 of the Patent License Agreement, or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement. 

“Contract Year” means any 12-month period indicated as the Contract Year in Section 1 of
the Patent License Agreement, or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement. 

“Diligent and Commercially Reasonable Efforts” means, as the case may be, exerting such efforts and employing such resources as would
normally and objectively be exerted or employed by a similarly situated company for a product of similar market potential, profit potential and strategic value at a similar stage of its product life, taking into account the competitiveness of the
relevant marketplace, the patent, intellectual property and development positions of Third Parties, the applicable regulatory situation, the pricing/reimbursement situation, the commercial viability of the product and other relevant development and
commercialization factors based upon then prevailing conditions. 
 “Distributor” means a distributor or reseller to which Licensee,
its Affiliates, or Sublicensees sells a Licensed Product for resale of Licensed Product by the Distributor, and for which resale or distribution Licensee, its Affiliates, or Sublicensees receives no further consideration (including but not limited
to royalties and/or commissions) beyond the price for the initial sale of Licensed Product to the Distributor. 
 “Effective Date”
means the date indicated as the Effective Date in Section 1 of the Patent License Agreement. 
 “Fair Market Value” means the
cash consideration an unaffiliated, unrelated buyer would pay in an arm’s length sale of a substantially identical item sold in the same quantity, under the same terms, and at the same time and place. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-1	 	Agreement No. [***]

 “Field” means the field indicated as the Field identified in Section 1 of the
Patent License Agreement. 
 “First Sale” means the first commercial sale to any Third Party of a Licensed Product in the Territory.

 “Force Majeure” means an unforeseeable act that prevents or delays a Party from performing one or more of its duties under this
Agreement and that is outside of the reasonable control of the affected Party. A Force Majeure includes without limitation acts of war or of nature, insurrection and riot, strikes, lockouts, or other serious labor disputes, epidemics, pandemics, and
widespread disease, and floods, fires, explosions, or other natural disasters. A Force Majeure does not include delays encountered in enrolling or pursuing clinical trials, or in seeking or receiving the approval of vaccine or drug regulators. 

“Government” means any agency, department, or other unit of the United States of America or the State of Texas. 

“Gross Consideration” means all cash and non-cash consideration (e.g., securities). 

“Improvements” means patentable inventions that (i) are owned by Licensor after the Effective Date, (ii) are not subject to
conflicting legal obligations under any other agreements, (iii) would require a license under the rights licensed under this Agreement to practice, and (iv) were developed in the laboratory of the principal investigator, [***], within
[***] of the Effective Date, and identified to Licensor as Improvements falling under this license. 
 “Licensed Process” means a
method or process whose practice or use of which would constitute, but for the license granted to Licensee under this Agreement, an infringement of any Valid Claim (or, in the case of an unissued Valid Claim, a method whose practice or use would be
covered by such Valid Claim). 
 “Licensed Product” means any product or component (i) whose manufacture, use, sale, offer for
sale or import would constitute, but for the license granted to Licensee under this Agreement, an infringement of any Valid Claim (or, in the case of an unissued Valid Claim, a product whose manufacture, use, sale, offer for sale or import would be
covered by such Valid Claim), or (ii) which is made using a Licensed Process. 
 “Licensee” means the Party identified as the
Licensee in Section 1 of the Patent License Agreement. 
 “Licensor” means the Party identified as the Licensor in
Section 1 of the Patent License Agreement. 
 “Milestone Fees” means all fees identified as Milestone Fees in
Section 3.1(b) of the Patent License Agreement. 
 “Net Product Sales” means the Sales to a Third Party of Licensed Products by
Licensee, its Affiliates, or Sublicensees less the following items directly attributable to such Sales that are specifically identified on the invoice for such Sales and borne by the Licensee, its Affiliates, or Sublicensees as the seller: [***]. On
sales of Licensed Products made in other than an arm’s length transaction, the value of the Net Product Sales attributed to such transaction will be equal to the customary sale price or, in if there is no customary sale price, the Fair Market
Value of such Licensed Products. Net Product Sales does not include [***], but does include [***]. For avoidance of doubt Net Product Sales are calculated on sales by [***]. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-2	 	Agreement No. [***]

 “Non-Royalty Sublicensing Consideration”
means the Gross Consideration received by the Licensee or its Affiliate from a Sublicensee in consideration of the grant of a sublicense under the Patent Rights [***], but excluding [***]. Non-Royalty
Sublicensing Consideration will not include: [***]. 
 “Patent License Agreement” means the particular Patent License Agreement to
which these Terms and Conditions are attached and incorporated into by reference. 
 “Patent Rights” means the Licensor’s rights
in (a) the patents and patent applications listed in Section 1 of the Patent License Agreement; (b) all non-provisional patent applications that claim priority to any provisional application
listed in Section 1 of the Patent License Agreement; and (c) all divisionals, continuations, and such claims of continuations-in-part as are entitled to claim
priority to the aforesaid patents and/or patent applications, and all reissues, reexaminations, extensions of, and foreign counterparts; and (e) any patents that issue with respect to the aforesaid patent applications. From time to time during
the term of the Agreement, upon written agreement by both Parties, Licensee and Licensor shall update the list of all patent applications and patents within the Patent Rights. 

“Prosecution Counsel” means the law firm or attorney who is handling the prosecution of the Patent Rights. Prosecution Counsel as of
the Effective Date is identified in Section 1 of the Patent License Agreement. 
 “Quarterly Payment Deadline” means the day
that is [***] after the last day of any particular Contract Quarter. 
 “Sell, Sale or Sold” means any transfer or other disposition
of Licensed Products for which consideration is received by Licensee, its Affiliates, or Sublicensees. A Sale of Licensed Products will be deemed completed at the time Licensee or its Affiliate or its Sublicensee receives such consideration. 

“Sublicense Agreement” means any agreement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to any Sublicensee a
sublicense under the Patent Rights. 
 “Sublicense Fee” means the fee specified in Section 3.1(d) of the Patent License
Agreement. 
 “Sublicensee” means any entity to which an express sublicense has been granted by Licensee under the Patent Rights.

 “Technology Rights” means Licensor’s rights which are owned and controlled by Licensor in technical information, know-how, processes, procedures, compositions, methods, formulas, protocols, techniques, designs, and non-clinical data created before the Effective Date by individuals in the
laboratory of the Principal Investigator while employed at Licensor which may not covered by a Valid Claim but which are necessary for practicing inventions claimed or described in patents and/or patent applications listed in the definition of
Patent Rights whether outstanding, expired or abandoned. Notwithstanding the foregoing, it is understood by Licensee that the university does not ordinarily claim or own the knowledge or techniques of university researchers that are not claimed in
patent applications or embodied in copyrighted software, and that such knowledge or techniques are typically owned by the researchers themselves. It is further understood that nothing in this Agreement implies an obligation on the part of university
researchers to dedicate time to assisting Licensee to commercially develop the technology licensed hereunder. Any assistance that Licensee needs from university researchers to develop the technology would need to be obtained through other
agreements. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-3	 	Agreement No. [***]

 “Territory” means the territory so indicated as the Territory in Section 1 of
the Patent License Agreement. 
 “Third Party” means an individual or entity other than Licensee, any Affiliate, or Licensor. 

“Valid Claim” means a claim of (i) an issued and unexpired patent included within the Patent Rights unless the claim has been held
unenforceable or invalid by the final, un-reversed, and un-appealable decision of a court or other government body of competent jurisdiction, has been irretrievably
abandoned or disclaimed, or has otherwise been finally admitted or determined to be invalid, un-patentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (ii) a
pending patent application within the Patent Rights to the extent the claim continues to be prosecuted in good faith. 
  

	2.	 License Grant and Commercialization 

 

	 	2.1	 Grant 

  

	 	(a)	 Licensor grants to Licensee and Affiliates a royalty-bearing exclusive license in the Exclusive Field, with the right to
sublicense through multiple tiers, under Patent Rights and Technology Rights, to manufacture, develop, use, Sell, distribute, lease, loan, offer for sale, import, and otherwise commercially exploit Licensed Products in the Field in the Territory,
and to have any of the foregoing performed. [***]. 

  

	 	(b)	 This grant is subject to (i) the payment by Licensee to Licensor of all consideration required under this Agreement,
(ii) any rights of, or obligations to, the Government as set forth in Section 11.2 (Government Rights), and (iii) non-commercial rights retained by Licensor to: 

 

	 	(1)	 Publish the scientific findings from research related to the Patent Rights; and 

 

	 	(2)	 Manufacture, have manufactured, and use the Patent Rights for teaching, academic research, education, and other
educationally-related purposes; and 

  

	 	(3)	 Grant rights to, and transfer material embodiments of, the Patent Rights to other academic institutions or non-profit research institutions for the purposes identified in clauses (1) and (2) above; 

provided that none of (1) through (3) include the right for Licensor to grant or transfer any rights exclusively licensed under this Agreement to
any Third Party for any commercial use. 
  

	 	(c)	 Licensor reserves all rights not expressly granted in the Agreement and disclaims the grant of any implied rights to
Licensee. 

  

	 	2.2	 Sublicensing 

Licensee has the right to grant Sublicense Agreements under the Patent Rights consistent with the terms of the Agreement, subject to the following: 

 

	 	(a)	 A Sublicense Agreement shall not exceed the scope and rights granted to Licensee hereunder. Sublicensee must agree in
writing to be bound by the applicable terms and conditions of the Agreement and shall indicate that Licensor is a third party 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-4	 	Agreement No. [***]

	 	
beneficiary and entitled to enforce the terms and conditions of the Sublicense Agreement applicable to the Agreement. In the event of termination of this Agreement, continued sublicense rights
shall be governed by Section 7.5(a) (Effect of Termination). Licensee may grant a Sublicensee the right to grant further sub-Sublicense Agreements, in which case such
sub-Sublicense Agreements shall be treated as “Sublicense Agreements” and such sub-Sublicensees shall be treated as “Sublicensees” for purposes of the Agreement. 

 

	 	(b)	 Licensee shall deliver to Licensor a true and correct copy (which may be redacted with respect to any terms that are not
relevant to Licensor’s rights and obligations under this Agreement) of each Sublicense Agreement granted by Licensee, Affiliate or Sublicensee, and any modification or termination thereof, within 30 days following the applicable execution,
modification, or termination of such Sublicense Agreement. If the Sublicense Agreement is not in English, Licensee shall provide Licensor an accurate English translation in addition to a copy of the original agreement. 

 

	 	(c)	 Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor for all of the
Licensee’s duties and obligations contained in this Agreement, including without limitation the payment of running royalties due under Section 3.2 whether or not paid to Licensee by a Sublicensee. Any act or omission of a Sublicensee that
would be a breach of this Agreement if performed by Licensee will be deemed to be a breach by Licensee unless Licensee complies with the remaining provisions of this paragraph. Each Sublicense Agreement will contain a right of termination by
Licensee in the event that the Sublicensee breaches the payment or reporting obligations affecting Licensor or any other terms and conditions of the Sublicense Agreement that would constitute a breach of this Agreement if such acts were performed by
Licensee. In the event of a Sublicensee breach, and if after a reasonable opportunity to cure as provided in any such Sublicense Agreement (not to exceed 30 days for a payment breach and 90 days for a
non-payment breach), such Sublicensee fails to cure such Sublicensee breach, then the Licensee will terminate the Sublicense Agreement within 30 days thereafter, with copy of such written notice of termination
to Licensor, unless agreed to in writing otherwise by Licensor. 

  

	 	2.5	 Diligent Commercialization 

Licensee by itself or through its Affiliates and Sublicensees will use diligent efforts to make Licensed Products commercially available in the Field in
the Territory. Without limiting the foregoing, Licensee will fulfill the milestone events specified in Section 2.4 of the Patent License Agreement by the deadlines indicated therein and will use Diligent and Commercially Reasonable Efforts to
(a) maintain a reasonably funded, ongoing and active research, development, manufacturing, regulatory, marketing or sales program required to make License Products commercially available, and (b) perform and complete the plans described in
the annual report submitted pursuant to Section 4.2 (Annual Written Progress Report). The milestone event deadlines set forth in Section 2.4 of the Patent License Agreement will be extended by the number of days of delay reasonably
attributable to a Force Majeure. In the event of a Force Majeure Licensee will give prompt notice to Licensor and the Parties shall meet and confer regarding the length of the required extension. If the milestone events specified in Section 2.4
of the Patent License Agreement are not met by the indicated deadlines or if the obligations under this Section 2.4 are not fulfilled, Licensor may treat such failure as a breach in accordance with Section 7.3(b). 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-5	 	Agreement No. [***]

 If Licensee determines that it will be unable to achieve a milestone event set forth in
Section 2.4 of the Patent License Agreement by any applicable deadlines indicated therein, [***]. 
  

	 	2.6	 Improvements 

For a period of [***] after the Effective Date, Licensor will provide reasonable written notice to Licensee of any Improvements, by providing a copy of
any invention disclosure disclosing such Improvement to Licensee under confidentiality restriction. Licensee will have the option, exercisable within [***] of receipt of such invention disclosure, to add such Improvements to the Patent Rights. If
Licensee exercises its option to add Improvements to the Patent Rights, the Parties shall execute an amendment to this Agreement explicitly adding such Improvements to the Patent Rights. 

 

	3.	 Compensation 

In consideration of rights granted to Licensee, Licensee will pay Licensor the following fees and royalties. All fees and royalties are not refundable
and are not creditable against other fees and royalties except as expressly set forth in this Agreement. Each payment will reference the Patent License Agreement number and will be sent to Licensor’s payment and accounting contact in
Section 18 (Notices) of the Patent License Agreement. 
  

	 	3.1	 Non-Royalty Payments due from Licensee 

 

	 	(a)	 Patent Expenses. Licensee will reimburse Licensor for the past patent expenses stated in Section 3.1(a) of
the Patent License Agreement within 30 days after the Effective Date. The stated amount is the current estimate for past patent expenses based on invoices received by the Licensor through the stated date. Licensee’s obligations to pay all past
and future patent expenses pursuant to Section 6 (Patent Expenses and Prosecution) will not be limited by such amount. 

  

	 	(b)	 Milestone Fees. Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent License Agreement
by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth in Section 3.1(b) of the Patent License Agreement are achieved. 

 

	 	(c)	 Scheduled License Fees. Licensee will pay license fees in the amounts set forth in Sections 3.1(c) of the Patent
License Agreement in accordance with the stated schedule. 

  

	 	(d)	 Sublicense Fees. Licensee will pay Sublicense Fees indicated in Section 3.1(d) of the Patent License
Agreement on or before the Quarterly Payment Deadline for the Contract Quarter in which the Non-Royalty Sublicensing Consideration resulting in such Sublicense Fees was received. 

 

	 	(e)	 Assignment Fee. Licensee will pay the assignment fee set forth in Section 3.1(e) of the Patent License
Agreement within 30 days after Licensee assigns all of Licensee’s right, title, and interest in and to this Agreement to a Third Party. 

  

	 	3.2	 Royalties 

Licensee will pay a running royalty at the rate set forth in Section 3.2 of the Patent License Agreement on Net Product Sales in each Contract
Quarter, payable on or before the Quarterly Payment Deadline for such Contract Quarter, subject to the following: 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-6	 	Agreement No. [***]

	 	(a)	 No more than one royalty shall be paid to Licensor hereunder with respect to the Sale of any one unit of Licensed
Product, whether or not more than one patent or Valid Claim is applicable to the Licensed Product, or the development, manufacture, or performance thereof. 

  

	 	(b)	 No royalty shall be payable under this Section 3.2 with respect to the Sale of Licensed Products between or among
Licensee, its Affiliates, and Sublicensees for re-sale purposes, provided Licensor is paid a royalty with respect to the re-sale, or (iii) payments that constitute Non-Royalty Sublicensing Consideration. 

  

	 	(c)	 If a Licensed Product cannot be exploited without infringing patent(s) or patent application(s) owned, licensed, or
controlled by a Third Party in the Territory, and Licensee licenses such Third Party patent(s) or patent application(s), then Licensee shall be entitled to deduct [***] of the royalty actually paid to any such Third Party for any such rights in the
Territory (such consideration, “Third Party Royalties”) from royalties due Licensor for the Net Product Sales of such Licensed Product in the Territory, provided that such amounts payable shall not be reduced, with respect to any
Contract Quarter, below [***] with respect to Single Vaccine Licensed Products and one and [***] of Net Product Sales with respect to Multiple Vaccine Licensed Products. 

 

	 	3.3	 Minimum Royalties 

If royalties paid to Licensor do not reach the minimum royalty amounts stated in Section 3.3 of the Patent License Agreement for the specified
periods, Licensee will pay Licensor on or before the Quarterly Payment Deadline for the last Contract Quarter in the stated period an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties paid
to Licensor. 
  

	 	3.4	 Non-cash Consideration 

If Licensee receives or anticipates receipt of non-cash consideration from Sales or Sublicenses, the manner in
which Licensor will receive its compensation under the Agreement with respect to such non-cash consideration will be negotiated in good faith and timely agreed to by the Parties. 

 

	4.	 Reports and Plans 

The reports specified in this Section 4 will be sent to Licensor’s payment and reporting contact identified in Section 18 (Notices) of
the Patent License Agreement. If Licensor requests to have information submitted in a particular format, Licensee will use reasonable efforts to comply with such request. 
  

	 	4.1	 Quarterly Royalty Payment and Milestone Reports 

On or before each Quarterly Payment Deadline, Licensee will deliver to Licensor a true and accurate report, certified by an officer of Licensee, giving
such particulars of the business conducted by Licensee, its Affiliates and its Sublicensees (including copies of reports provided by Sublicensees and Affiliates to Licensee) during the preceding Contract Quarter under the Agreement as necessary for
Licensor to account for Licensee’s payments hereunder, even if no payments are due. The reports shall continue to be delivered after the termination or expiration of the Agreement until such time as all Licensed Products permitted to be Sold
after termination or expiration have been Sold or destroyed. Licensee shall provide information in sufficient detail to enable the royalties payable hereunder to be determined and to calculate all of the amounts payable under the Agreement. The
report shall include: 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-7	 	Agreement No. [***]

	 	(a)	 The name of the Licensee, the Patent License Agreement number, and the period covered by the report;

  

	 	(b)	 The name of any Affiliates and Sublicensees whose activities are also covered by the report; 

 

	 	(c)	 Identification of each Licensed Product for which any royalty payments have become payable; 

 

	 	(d)	 Net Product Sales segregated on a
product-by-product basis, and a country-by-country basis, or an affirmative statement
that no Sales were made. The report shall also itemize the permitted deductions from the gross Sales used to arrive at the resulting Net Product Sales, on a
product-by-product and country-by-country basis; 

 

	 	(e)	 The applicable royalty rate; 

  

	 	(f)	 An affirmative statement of whether any milestones with deadlines in that Contract Quarter under Section 2.4 and any
milestones under Section 3.1(b) were met or not, and the resulting Milestone Fee payable; 

  

	 	(g)	 Non-Royalty Sublicensing Consideration received by Licensee segregated on a Sublicense-by-Sublicense basis, or an affirmative statement that none was received; 

 

	 	(h)	 If any consideration was received in currencies other than U.S. dollars, the report shall describe the currency exchange
calculations; and 

  

	 	(i)	 Any changes in accounting methodologies used to account for and calculate the items included in the report since the
previous report. 

  

	 	4.2	 Annual Written Progress Report and Commercialization Plan 

Within [***] following the end of each Contract Year, Licensee will deliver to Licensor a true and accurate written progress report and
commercialization plan that summarizes (i) Licensee’s efforts and accomplishments during the Contract Year to use Diligence and Commercially Reasonable Efforts to develop and commercialize Licensed Products, and (ii) Licensee’s
development and commercialization plans with respect to Licensed Products for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees. The report shall contain the following information to the extent
relevant to the activities under the Agreement: 
  

	 	(a)	 The name of the Licensee, the Patent License Agreement number, the names of any Affiliates and Sublicensees, and the
products being developed and/or commercialized; 

  

	 	(b)	 The progress toward completing and the plans for completing the applicable milestone events pursuant to Sections 2.4 and
3.1(b); 

  

	 	(c)	 The research and development activities, including status and plans for clinical trial initiations or readouts as well as
obtaining any necessary governmental approvals, completed during the past year, and the plans for research and development activities for the next year; and 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-8	 	Agreement No. [***]

	 	(d)	 The marketing activities for the past year. 

 

	 	4.3	 Government and Economic Development Reporting 

If Licensor requests, Licensee will provide the information required under Federal and state law for Licensor’s Government and economic development
reporting purposes. This information shall be treated as Licensee’s Confidential Information; provided that Licensor is entitled to combine such information with similar information from other Licensor licensees and publicly report such
combined aggregate information, without identifying Licensee’s separate specific applicable numbers. If and when Licensee has more than 200 full-time employees, then no further economic development reports will be required from Licensee. 

 

	5.	 Payment, Records, and Audits 

 

	 	5.1	 Payments 

All amounts referred to in the Patent License Agreement are expressed in U.S. dollars without deductions for taxes, assessments, fees, or charges of any
kind. Each payment will reference the agreement number set forth at the beginning of the Patent License Agreement. All payments to Licensor will be made in U.S. dollars by check or wire transfer (Licensee to pay all wire transfer fees) payable to
the payee identified in Section 18 of the Patent License Agreement and sent to the payment and reporting contact in Section 18 (Notices) of the Patent License Agreement. 

 

	 	5.2	 Sales Outside the U.S. 

If any currency conversion shall be required in connection with the calculation of payments hereunder, such conversion shall be made using the rate used
by Licensee for its financial reporting purposes in accordance with U.S. Generally Accepted Accounting Principles (or foreign equivalent) or, in the absence of such rate, using the average of the buying and selling exchange rate for conversion
between the foreign currency and U.S. Dollars, for current transactions as reported in The Wall Street Journal on the last business days of the Contract Quarter to which such payment pertains. Licensor agrees to supply to Licensee, upon
written request, appropriate evidence from appropriate U.S. governmental agencies showing that Licensor is a resident of the United States of America for purposes of the U.S. income tax laws and is
tax-exempt under such income tax laws. 
  

	 	5.3	 Late Payments 

Amounts that are not paid within [***] after due will accrue a late charge from the due date until paid, at the prime rate as reported in The Wall
Street Journal on the last business days of the Contract Quarter to which such payment pertains (or the maximum allowed by law, if less). 
  

	 	5.4	 Records 

For a period of [***] after the Contract Quarter to which the records pertain, Licensee agrees that it and its Affiliates and Sublicensees will each
keep complete and accurate records of their Sales, Net Product Sales, Milestone Fees, and Non-Royalty Sublicensing Consideration in sufficient detail to enable such payments to be determined and audited. 

 

	 	5.5	 Auditing 

Licensee and its Affiliates will permit Licensor or its representatives, at Licensor’s expense, to periodically examine books, ledgers, and records
during regular business hours, at Licensee’s or its Affiliate’s place of business, on at least 30 days advance notice, to the extent necessary to verify any payment or report required under the Agreement. For each

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-9	 	Agreement No. [***]

 
Sublicensee, Licensee shall obtain such audit rights for Licensor or itself. If Licensee obtains such audit rights for itself, it will promptly conduct an audit of the Sublicensee’s records
upon Licensor’s request, and Licensee will furnish to Licensor a copy of the findings from such audit. No more than one audit of Licensee, each Affiliate, and each Sublicensee shall be conducted under this Section 5.5 in any calendar year.
If any amounts due Licensor have been underpaid, then Licensee shall immediately pay Licensor the amount of such underpayment plus accrued interest due in accordance with Section 5.3. If the amount of underpayment is equal to or greater than
[***] of the total amount due for the records so examined, Licensee will pay the cost of such audit. Such audits may, at Licensor’s sole discretion, consist of a self-audit conducted by Licensee at Licensee’s expense and certified in
writing by an authorized officer of Licensee. All information examined pursuant to this Section 5.5 shall be deemed to be the Confidential Information of the Licensee. Further, whenever Licensee and/or its Affiliates and Sublicensees has its
books and records audited by an independent certified public accountant, Licensee and/or its Affiliates and Sublicensees will, within [***] of the conclusion of such audit, at Licensor’s written request, provide Licensor with a written
statement of said auditor, setting forth the calculation of amounts due to Licensor over the time period audited, as determined from the books and records of the Licensee, Affiliate or Sublicensee; but said auditor does not need to give any audit
opinion with said statement. 
  

	6.	 Patent Expenses and Prosecution 

 

	 	6.1	 Patent Expenses 

[***], and [***] incurred by Licensor, for so long as, and in such countries as the Agreement remains in effect. [***]. Licensee will pay such patent
expenses (except for the payment called for under Section 3.1(a), [***] that have not been invoiced as of the date indicated in Section 3.1(a) of the Patent License Agreement and future expenses, within 30 days after Licensee’s
receipt of an invoice. Patent expense payment delinquencies will be considered a payment default under Section 7.3(a). 
  

	 	6.2	 Direction of Prosecution 

Licensor will confer with Licensee, [***], to develop a strategy for the prosecution and maintenance of Patent Rights. Licensor will request that copies
of all documents prepared by the Prosecution Counsel for submission to governmental patent offices be provided to Licensee for review and comment prior to filing, to the extent practicable under the circumstances and shall consider suggestions of
Licensee [***] in good faith. Licensor will defer to the prosecution strategy chosen by Licensee [***] except to the extent such strategy would materially impair commercialization of the Patent Rights in fields outside of the Exclusive Field, [***].
Notwithstanding the foregoing, Licensor [***] and Licensor reserves the right to instruct prosecution of additional claims to cover products or services outside the Exclusive Field, such as [***], at the Licensor’s own expense. The Parties
agree that they share a common legal interest to get valid enforceable patents and that Licensee will maintain as privileged all information received pursuant to this Section. 

 

	 	6.3	 Ownership 

All patent applications and patents will be in the name of Licensor (and any co-owner identified in
Section 1 of the Patent License Agreement) and owned by Licensor (and such co-owner, if any). No payments due under the Agreement will be reduced as the result of
co-ownership interests in the Patent Rights by Licensee or any other party. 
  

	 	6.4	 Foreign Filings 

In addition to the U.S., the Patent Rights shall, subject to applicable bar dates, be pursued in such foreign countries as Licensee so designates in
writing to Licensor in sufficient time 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-10	 	Agreement No. [***]

 
to reasonably enable the preparation of such additional filings, and in those foreign countries in which Licensor has filed applications prior to the Effective Date. If Licensee does not choose
to pursue patent rights in a particular foreign country and Licensor chooses to do so, Licensor shall so notify Licensee and thereafter said patent application or patent shall no longer be included in the Patent Rights and Licensee shall have no
further rights thereto. Licensor shall have the right to make alternative arrangements with Licensee for upfront payment of foreign patent expenses. 
  

	 	6.5	 Withdrawal from Paying Patent Costs 

If at any time Licensee wishes to cease paying for any costs for a particular Patent Right or for patent prosecution in a particular jurisdiction,
Licensee must give Licensor at least 90 days prior written notice and Licensee will continue to be obligated to pay for the patent costs which reasonably accrue during said notice period. Thereafter, said patent application or patent shall no longer
be included in the Patent Rights and Licensee shall have no further rights thereto. 
  

	 	6.6	 U.S. Patent and Trademark Office Entity Size Status 

Licensee represents that as of the Effective Date the entity size status of Licensee in accordance with the regulations of the U.S. Patent and Trademark
Office is as set forth in Section 1 of the Patent License Agreement. Licensee will inform Licensor in writing on a timely basis of any change in its U.S. Patent and Trademark Office entity size status. 

 

	7.	 Term and Termination 

  

	 	7.1	 Term 

Unless earlier terminated as provided herein, the term of this Agreement will commence on the Effective Date and continue until the last date of
expiration or termination of the Patent Rights. 
  

	 	7.2	 Termination by Licensee 

Licensee, at its option, may terminate this Agreement by providing Licensor written notice of intent to terminate, which such termination effective will
be 30 days following receipt of such notice by Licensor. 
  

	 	7.3	 Termination by Licensor 

Licensor, at its option, may immediately terminate the Agreement, or any part of Patent Rights, or any part of Field, or any part of Territory, or the
exclusive nature of the license grant, upon delivery of written notice to Licensee of Licensor’s decision to terminate, if any of the following occur: 
  

	 	(a)	 Licensee becomes in arrears in any payments due under the Agreement, and Licensee fails to make the required payment
within [***] days after delivery of written notice from Licensor, [***]; or 

  

	 	(b)	 Licensee is in breach of any non-payment provision of the Agreement, and does not
cure such breach within [***] days after delivery of written notice from Licensor; or 

  

	 	(c)	 Licensor delivers notice to Licensee of three or more actual breaches of the Agreement in any [***], even in the event
that Licensee cures such breaches in the allowed period; or 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-11	 	Agreement No. [***]

	 	(d)	 Licensee or its Affiliate or Sublicensee initiates any proceeding or action to challenge the validity, enforceability, or
scope of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding or action. 

[***]. 
  

	 	7.4	 Other Conditions of Termination 

The Agreement will terminate: 
  

	 	(a)	 Immediately (but only to the extent permitted by applicable law), (i) if Licensee becomes bankrupt or insolvent, or
(ii) Licensee’s Board of Directors elects to liquidate its assets or dissolve its business, or (iii) Licensee ceases its business operations, or (iv) Licensee makes an assignment for the benefit of creditors or (v) if the
business or assets of Licensee are otherwise placed in the hands of a receiver or trustee, whether by voluntary act of Licensee or otherwise; or 

  

	 	(b)	 At any time by mutual written agreement between Licensee and Licensor. 

 

	 	7.5	 Effect of Termination 

If the Agreement is terminated for any reason: 
  

	 	(a)	 All rights and licenses of Sublicensees shall terminate upon termination of the Agreement; provided however, if the
Sublicense Agreement is in good standing and agrees in writing to assume all of the obligations of Licensee with respect to the rights sublicensed under this Agreement and provides Licensor with written notice thereof within 30 days after
termination of the Agreement, then such Sublicense Agreement shall survive; and 

  

	 	(b)	 Licensee shall cease making, having made, distributing, having distributed, using, selling, offering to sell, leasing,
loaning and importing any Licensed Products by the effective date of termination; and 

  

	 	(c)	 Licensee shall tender payment of all accrued royalties and other payments due to Licensor as of the effective date of
termination; and 

  

	 	(d)	 Nothing in the Agreement will be construed to release either Party from any obligation that matured prior to the
effective date of termination; and 

  

	 	(e)	 The provisions of Section 2.1 (with respect to Technology Rights), Sections 8 (Confidentiality), 9 (Infringement and
Litigation), 11 (Representations and Disclaimers), 12 (Limit of Liability), 13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General Provisions) will survive any termination or expiration of the Agreement. In addition,
the provisions of Sections 3 (Compensation), 4.1 (Quarterly Payment and Milestone Reports), 5 (Payment, Records and Audits), and 6.1 (Patent Expenses) shall survive with respect to all activities and payment obligations accruing prior to the
termination or expiration of the Agreement. 

  

	8.	 Confidentiality 

  

	 	8.1	 Definition 

“Confidential Information” means all information that is of a confidential and proprietary nature to Licensor or Licensee and provided
by one Party to the other Party under this 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-12	 	Agreement No. [***]

 
Agreement or the [***], provided that, except as set forth in section 8.3 below, the provisions applicable to Confidential Information herein are not intended to replace any additional or more
restrictive requirements for handling Confidential Information, if any, imposed under [***]. 
  

	 	8.2	 Protection and Marking 

Licensor and Licensee each agree that all Confidential Information disclosed in tangible form, and marked “confidential” and forwarded to the
receiving Party by the disclosing Party, or if disclosed orally, is designated as confidential at the time of disclosure: (i) is to be held in strict confidence by the receiving Party, (ii) is to be used by and under authority of the
receiving Party only as authorized in the Agreement, and (iii) shall not be disclosed by the receiving Party, its agents or employees without the prior written consent of the disclosing Party or as authorized in the Agreement. Licensee has the
right to use and disclose Confidential Information of Licensor reasonably in connection with the exercise of its rights under the Agreement, including without limitation disclosing to Affiliates, actual or potential Sublicensees, investors,
acquirers, and others on a need to know basis, if such Confidential Information is provided under conditions which reasonably protect the confidentiality thereof. Each Party’s obligation of confidence hereunder includes, without limitation,
using at least the same degree of care with the disclosing Party’s Confidential Information as it uses to protect its own Confidential Information, but always at least a reasonable degree of care. 

 

	 	8.3	 Confidentiality or Terms of Agreement 

Each Party agrees not to disclose to any Third Party the terms of the Agreement without the prior written consent of the other Party hereto, except each
Party may disclose the Confidential Information of the other Party and the terms of the Agreement or the MTA (including without limitation any data or results obtained by the Licensee under the MTA): (a) to advisors, actual or potential
Sublicensees, investors, acquirers, and others on a need to know basis, in each case, under appropriate confidentiality obligations substantially similar to those of this Section 8; and (b) to the extent necessary to comply with applicable
laws (including the rules of regulatory agencies and securities exchanges) and court orders (including, without limitation, The Texas Public Information Act, as may be amended from time to time, other open records laws, decisions and rulings, and
securities laws, regulations and guidance). Licensee may also disclose Licensor’s Confidential Information to the extent (and only to the extent) such disclosure is reasonably necessary in connection with preparing, filing or seeking marketing
approvals and other regulatory filings for the Licensed Product, to the Government and applicable regulatory agencies. If the Agreement is not for all fields of use, then Licensor may disclose the Field to other potential third party licensees.
Notwithstanding the foregoing, the existence of the Agreement shall not be considered Confidential Information. 
  

	 	8.4	 Disclosure Required by Court Order or Law 

If the receiving Party is required to disclose Confidential Information of another Party hereto, or any terms of the Agreement, pursuant to the order or
requirement of a court, administrative agency, or other governmental body or applicable law, the receiving Party may disclose such Confidential Information or terms to the extent required, provided that the receiving Party shall use reasonable
efforts to provide the disclosing Party with reasonable advance notice thereof to enable the disclosing Party to seek a protective order and otherwise seek to prevent such disclosure. To the extent that Confidential Information so disclosed does not
become part of the public domain by virtue of such disclosure, it shall remain Confidential Information protected pursuant to Section 8. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-13	 	Agreement No. [***]

	 	8.5	 Copies 

Each Party agrees not to copy or record any of the Confidential Information of the other Party, except as reasonably necessary to exercise its rights or
perform its obligations under the Agreement, and for archival and legal purposes. 
  

	 	8.6	 Continuing Obligations 

Subject to the exclusions listed in Section 8.7, the Parties’ confidentiality obligations under the Agreement will survive termination of the
Agreement and will continue for a period of [***] thereafter. 
  

	 	8.7	 Exclusions 

Information shall not be considered Confidential Information of a disclosing Party under the Agreement to the extent that the receiving Party can
establish by competent written proof that such information: 
  

	 	(a)	 Was in the public domain at the time of disclosure; or 

 

	 	(b)	 Later became part of the public domain through no act or omission of the recipient Party, its employees, agents,
successors or assigns in breach of the Agreement; or 

  

	 	(c)	 Was lawfully disclosed to the recipient Party by a third party having the right to disclose it not under an obligation of
confidentiality; or 

  

	 	(d)	 Was already known by the recipient Party at the time of disclosure; or 

 

	 	(e)	 Was independently developed by the recipient Party without use of the disclosing Party’s Confidential Information.

  

	 	8.8	 Copyright Notice 

The placement of a copyright notice on any Confidential Information will not be construed to mean that such information has been published and will not
release the other Party from its obligation of confidentiality hereunder 
  

	9.	 Infringement and Litigation 

 

	 	9.1	 Infringement Notification and Conference  

If either Licensee or Licensor’s designated office for technology commercialization becomes aware of any suspected infringement of Patent Rights in
the Field, such Party shall promptly notify the other Party of such in writing; and the Parties will confer regarding any such suspected infringement. Notice of infringement may be given to a suspected infringer only with the prior written consent
of each of the Parties, not to be unreasonably withheld, delayed, or conditioned. If any suit is to be commenced, Licensor and Licensee will endeavor to reach mutual agreement as to how best to prosecute, manage, and fund such suit. Any net recovery
resulting from such suit shall be first used to reimburse each Party’s expenses incurred directly in such prosecution and management, and the remainder shall [***]. 
  

	 	9.2	 Licensee’s Enforcement Rights 

Licensee has the first right to institute an infringement suit, but only with the prior written consent of Licensor, which will not be unreasonably
withheld, delayed or conditioned, and only for an infringement of Patent Rights that have been licensed exclusively to Licensee in the Exclusive Field. In such case, Licensee will keep Licensor reasonably informed of the developments and status of
the suit. Licensee will obtain Licensor’s input and approval on 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-14	 	Agreement No. [***]

 
any substantive positions taken in the suit regarding the scope, validity, and enforceability of the Patent Rights. Licensee shall not prosecute, settle, or otherwise compromise any such suit in
a manner that adversely affects Licensor’s interests or the public’s interests, without Licensor’s prior written consent. 
  

	 	9.4	 Indispensable Party 

If it is necessary to name Licensor as a party plaintiff in such infringement suit, then Licensee must first obtain Licensor’s prior written
permission, which permission shall not be unreasonably withheld, delayed, or conditioned, provided that (i) Licensor shall have reasonable prior input on choice of counsel on any matter where such counsel represents Licensor’s interests,
and (ii) Licensee and such counsel agree to follow all required procedures of the Texas Attorney General regarding retention of outside counsel for state entities, and (iii) Licensee shall bear, and indemnify Licensor for, all costs and
liabilities related to Licensor being named a party plaintiff in such suit. 
  

	 	9.5	 Cooperation between Licensor and Licensee 

In any infringement suit matter, the Parties agree to cooperate fully with each other. At the request of the Party bringing suit, the other Party will
permit reasonable access after reasonable advance notice, to all relevant personnel, records, papers, information, samples, specimens, etc., during regular business hours. 
  

	10.	 Export Compliance 

Licensee understands that the Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the
Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and
regulations include (but are not limited to): (a) ITAR and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements; (c) ITAR and EAR end user-specific requirements; (d) Foreign
Corrupt Practices Act; and (e) anti-boycott laws and regulations. Licensee will comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the
Licensed Products (including any associated products, items, articles, computer software, media, services, technical data, and other information). Licensee certifies that it will not, directly or indirectly, export (including any deemed export), nor
re-export (including any deemed re-export) the Licensed Products (including any associated products, items, articles, computer software, media, services, technical data,
and other information) in violation of applicable U.S. laws and regulations. Licensee will include a provision in its agreements, substantially similar to this Section 10, with its Sublicensees, third party wholesalers and distributors, and
physicians, hospitals or other healthcare providers who purchase a Licensed Product, requiring that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations. 

 

	11.	 Representations and Disclaimers 

 

	 	11.1	 Licensor Representations 

Except for the rights, if any, of the Government as set forth in Section 11.2, Licensor represents and warrants to Licensee that to the knowledge
of Licensor’s designated office for technology commercialization (i) Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights (other than the right, title and interest of any joint owner identified in
Section 1 of the Patent License Agreement), (ii) Licensor has the right to grant licenses hereunder, and (iii) Licensor has not knowingly granted and will not knowingly grant licenses or other rights under the Patent Rights that are in
conflict with the terms and conditions in the Agreement. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-15	 	Agreement No. [***]

	 	11.2	 Government Rights 

Licensee understands that Improvements may be developed under a funding agreement with Government and, if so, that Government may have certain rights
relative thereto. The Agreement is made subject to the Government’s rights under any such agreement and under any applicable Government law or regulation. To the extent that there is a conflict between any such agreement, such applicable law or
regulation and the Agreement, the terms of such Government agreement, and applicable law or regulation, shall prevail. Licensee agrees that, to the extent required by U.S. laws and regulations, Licensed Products used or Sold in the U.S. will be
manufactured substantially in the U.S., unless a written waiver is obtained in advance from the U.S. Government. 
  

	 	11.3	 Licensor Disclaimers 

EXCEPT AS SPECIFICALLY SET FORTH IN SECTION 11.1, LICENSEE UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE LICENSED PRODUCTS, OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE, MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF
DEVELOPMENT, PATENTABILITY, AND/OR BREADTH OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY LICENSOR
THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN FIELD. NOTHING IN THIS AGREEMENT WILL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY OTHER THAN THE PATENT RIGHTS, WHETHER SUCH
PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS. 
  

	 	11.4	 Licensee Representation 

By execution of the Agreement, Licensee represents, acknowledges, covenants and agrees (a) that Licensee has not been induced in any way by
Licensor or its employees to enter into the Agreement, and (b) that Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items and issues pertaining to this Section 11 (Representations and
Disclaimers) and all other matters pertaining to the Agreement; and (c) that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due diligence. Licensee represents that
it is a duly organized, validly existing entity of the form indicated in Section 1 of the Patent License Agreement, and is in good standing under the laws of its jurisdiction of organization as indicated in Section 1 of the Patent License
Agreement, and has all necessary corporate or other appropriate power and authority to execute, deliver and perform its obligations hereunder. 
  

	12.	 Limit of Liability 

IN NO EVENT SHALL LICENSOR, THE UNIVERSITY SYSTEM IT GOVERNS, ITS MEMBER INSTITUTIONS, INVENTORS, REGENTS, OFFICERS, EMPLOYEES, STUDENTS, AGENTS OR
AFFILIATED ENTERPRISES, BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS
SUBJECT MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. OTHER THAN FOR CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION (SECTION 13) OR FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT OF
LICENSOR’S INTELLECTUAL PROPERTY RIGHTS, LICENSEE AND ITS AFFILIATES WILL NOT BE LIABLE TO LICENSOR FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-16	 	Agreement No. [***]

 
LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE KNOWS OR SHOULD HAVE KNOWN OF THE
POSSIBILITY OF SUCH DAMAGES. 
  

	13.	 Indemnification 

  

	 	13.1	 Indemnification Obligation 

Subject to Section 13.2, Licensee agrees to hold harmless, defend and indemnify Licensor, the university system it governs, its member
institutions, its Regents, officers, employees, students and agents (“Indemnified Parties”) from and against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses, costs and expenses
(including, without limitation, reasonable attorneys’ fees and other expenses of litigation) (collectively “Liabilities”) resulting from claims or demands brought by Third Parties against an Indemnified Party on account of any
injury or death of persons, damage to property, or any other damage or loss arising out of or in connection with the Agreement or the exercise or practice by or under authority of Licensee, its Affiliates or their Sublicensees, or Third Party
wholesalers or distributors, or physicians, hospitals or other healthcare providers who purchase a Licensed Product, of the rights granted hereunder. 
  

	 	13.2	 Conditions of Indemnification 

Licensee shall have no responsibility or obligation under Section 13.1 for any Liabilities to the extent caused by the gross negligence or willful
misconduct any Indemnified Party or breach of this Agreement by Licensor. Obligations to indemnify, and hold harmless under Section 13.1 are subject to: (a) to the extent authorized by the Texas Constitution and the laws of the State of
Texas, and subject to the statutory duties of the Texas Attorney General, the Indemnified Party giving Licensee control of the defense and settlement of the claim and demand; and (b) to the extent authorized by the Texas Constitution and the
laws of the State of Texas and subject to statutory duties of the Texas Attorney General, the Indemnified Party providing assistance reasonably requested by Licensee, at Licensee’s expense. 

 

	14.	 Insurance 

  

	 	14.1	 Insurance Requirements 

Prior to any Licensed Product being used or Sold (including for the purpose of obtaining regulatory approvals), by Licensee, an Affiliate, or by a
Sublicensee, and for a period of [***] after the Agreement expires or is terminated, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in commercially reasonable and appropriate amounts for the
Licensed Product being used or Sold. Licensee shall use commercially reasonable efforts to have Licensor, the university system it governs, its member institutions, Regents, officers, employees, students, and agents named as additional insureds.
Such commercial general liability insurance shall provide, without limitation: [***]. 
  

	 	14.2	 Evidence of Insurance and Notice of Changes 

Upon request by Licensor, Licensee shall provide Licensor with written evidence of such insurance. Additionally, Licensee shall provide Licensor with
written notice of at least 60 days prior to Licensee cancelling, not renewing, or changing such insurance to the extent materially adversely impacting Licensor. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-17	 	Agreement No. [***]

	15.	 Assignment 

The Agreement may not be assigned by Licensee without the prior written consent of Licensor, which consent will not be unreasonably withheld, delayed or
conditioned. A merger or other transaction in which the equity holders of Licensee prior to such event hold less than a majority of the equity of the surviving or acquiring entity shall be considered an assignment of the Agreement. [***]. For any
permitted assignment to be effective, (a) Licensee must be in good standing under this Agreement, (b) the Licensee must pay Licensor the assignment fee pursuant to Section 3.1(e) (except in the case of any assignment to an Affiliate),
and (c) the assignee must assume in writing (a copy of which shall be promptly provided to Licensor) all of Licensee’s rights, duties and obligations (including curing all Licensee defaults existing at the time of assignment within 30 days
of execution of the assignment) under the Agreement and agree to comply with all terms and conditions of the Agreement as if assignee were an original Party to the Agreement. 
  

	16.	 Governmental Markings 

  

	 	16.1	 Patent Markings 

Licensee agrees to use Diligence and Commercially Reasonable Efforts to ensure that all Licensed Products Sold by Licensee, Affiliates, or Sublicensees
will be legibly marked with the number of any applicable patent(s) licensed hereunder as part of the Patent Rights in accordance with each country’s patent marking laws, including Title 35, U.S. Code, or if such marking is not practicable,
to mark the accompanying outer box or product insert for Licensed Products accordingly. 
  

	 	16.2	 Governmental Approvals and Marketing of Licensed Products  

Licensee will be responsible for obtaining all necessary governmental approvals for the development, production, distribution, Sale, and use of any
Licensed Product, at Licensee’s expense, including, without limitation, any safety studies. Licensee will have sole responsibility for any warning labels, packaging and instructions as to the use and the quality control for any Licensed
Product. 
  

	 	16.3	 Foreign Registration and Laws  

Licensee agrees to register the Agreement with any foreign governmental agency that requires such registration; and Licensee will pay all costs and
legal fees in connection with such registration. Licensee is responsible for compliance with all foreign laws affecting the Agreement or the Sale of Licensed Products to the extent there is no conflict with United States law, in which case United
States law will control. 
  

	17.	 Use of Name 

Licensee will not use the name, trademarks or other marks of Licensor (or the name of the university system it governs, its member institutions, any of
its Regents or employees) without the advance written consent of Licensor. Licensor may use Licensee’s name and logo for annual reports, brochures, website, and internal reports without prior consent. 

 

	18.	 Notices 

Any notice or other communication of the Parties required or permitted to be given or made under the Agreement will be in writing and will be deemed
effective when sent in a manner that provides confirmation or acknowledgement of delivery and received at the address set forth in Section 18 of the Patent License Agreement (or as changed by written notice pursuant to this Section 18).
Notices required under the Agreement may be delivered via E-mail provided such notice is confirmed in writing as indicated. 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-18	 	Agreement No. [***]

 Notices shall be provided to each Party as specified in the “Contact for Notice” address set
forth in Section 18 of the Patent License Agreement. Each Party shall update the other Party in writing with any changes in such contact information. 
  

	19.	 General Provisions 

  

	 	19.1	 Binding Effect 

The Agreement is binding upon and inures to the benefit of the Parties hereto, their respective executors, administrators, heirs, permitted assigns, and
permitted successors in interest. 
  

	 	19.2	 Construction of Agreement 

Headings are included for convenience only and will not be used to construe the Agreement. The Parties acknowledge and agree that both Parties
substantially participated in negotiating the provisions of the Agreement; therefore, both Parties agree that any ambiguity in the Agreement shall not be construed more favorably toward one Party than the other Party, regardless of which Party
primarily drafted the Agreement. 
  

	 	19.3	 Counterparts and Signatures 

The Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one
and the same instrument. A Party may evidence its execution and delivery of the Agreement by transmission of a signed copy of the Agreement via facsimile or email. 
  

	 	19.4	 Compliance with Laws 

Licensee will comply with all applicable federal, state, and local laws and regulations, including, without limitation, all export laws and regulations.

  

	 	19.5	 Force Majeure 

Neither Party shall be liable to the other for its failure to perform any of its obligations under this Agreement, except for payment obligations,
during any period in which such performance is delayed because rendered impracticable or impossible due to Force Majeure, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

 

	 	19.6	 Governing Law 

The Agreement will be construed and enforced in accordance with laws of the U.S. and the State of Texas, without regard to choice of law and conflicts
of law principles. 
  

	 	19.7	 Modification 

Any modification of the Agreement will be effective only if it is in writing and signed by duly authorized representatives of both Parties. No
modification will be made by email communications. 
  

	 	19.8	 Severability 

If any provision hereof is held to be invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid,
legal and enforceable substitute provision that most nearly reflects the original intent of the Parties, and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be construed in order to carry out the
intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality, or unenforceability shall not affect the validity, legality, or enforceability 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-19	 	Agreement No. [***]

 
of such other provisions in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable. 

 

	 	19.9	 Third Party Beneficiaries 

Nothing in the Agreement, express or implied, is intended to confer any benefits, rights or remedies on any entity, other than the Parties and their
permitted successors and assigns. However, if there is a joint owner of any Patent Rights identified in Section 1 of the Patent License Agreement (other than Licensee), then Licensee hereby agrees that the following provisions of these Terms
and Conditions extend to the benefit of the co-owner identified therein (excluding the Licensee to the extent it is a co-owner) as if such
co-owner was identified in each reference to the Licensor: the retained rights under clause (b) of Section 2.1; Section 11.3 (Licensor Disclaimers); Section 12 (Limitation of Liability);
Section 13 (Indemnification); Section 14.1 (Insurance Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable). 
  

	 	19.10	 Waiver 

Neither Party will be deemed to have waived any of its rights under the Agreement unless the waiver is in writing and signed by such Party. No delay or
omission of a Party in exercising or enforcing a right or remedy under the Agreement shall operate as a waiver thereof. 
  

	 	19.11	 Sovereign Immunity 

Nothing in the Agreement shall be deemed or treated as any waiver of Licensor’s sovereign immunity. 

 

	 	19.12	 Entire Agreement 

The Agreement and the MTA constitute the entire Agreement between the Parties regarding the subject matter hereof, and supersedes all prior written or
verbal agreements, representations and understandings relative to such matters. 
  

	 	19.13	 Claims Against Licensor for Breach of Agreement 

Licensee acknowledges that any claim for breach of the Agreement asserted by Licensee against Licensor shall be subject to Chapter 2260 of the Texas
Government Code and that the process provided therein shall be Licensee’s sole and exclusive process for seeking a remedy for any and all alleged breaches of the Agreement by Licensor or the State of Texas. 

— END OF EXHIBIT A — 

  

					
	Licensee:  Icosavax, Inc.	 	CONFIDENTIAL	 	Exclusive PLA Exhibit A
	The University of Texas at Austin	 	Page A-20	 	Agreement No. [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]